IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

Notes

01.01.–31.03.2024

01.01.–31.03.2023

Operating income

Gains from securities

3

270 709

Foreign exchange gains

644

Other income

5

5

270 714

649

Operating expenses

Losses from securities

3

(243 214)

Finance expenses

(1 435)

(1 108)

Foreign exchange losses

(16)

Administrative expenses

6

(7 525)

(8 943)

Other expenses

(1 225)

(1 223)

(10 201)

(254 488)

Profit/(loss) before tax

7

260 513

(253 839)

Income taxes

(19)

(16)

Profit/(loss) for the period

260 494

(253 855)

Total comprehensive profit/(loss) for the period

260 494

(253 855)

Earnings per share in CHF

8

4.75

(4.63)

Diluted earnings per share in CHF

8

4.75

(4.63)

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer